The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
[ 18 F]FDG-PET is superior to [ 123 I]IBZM-SPECT for the differential diagnosis of parkinsonism
Abstract
OBJECTIVE: Imaging of regional cerebral glucose metabolism with PET and striatal dopamine D2/D3 receptors (D2R) with SPECT improves the differential diagnosis of parkinsonism. We prospectively investigated 1) the diagnostic merits of these approaches in differentiating between Lewy body diseases (LBD; majority Parkinson disease [PD]) and atypical parkinsonian syndromes (APS); 2) the diagnostic value of [¹⁸F]fluorodeoxyglucose (FDG)-PET to differentiate among APS subgroups. METHODS: Ninety-five of 107 consecutive patients with clinically suspected APS referred for imaging were recruited. [¹⁸F]FDG-PET scans were analyzed by visual assessment (including individual voxel-based statistical maps). Based on a priori defined disease-specific patterns, patients with putative APS were differentiated from LBD (first level) and allocated to the subgroups multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal degeneration (CBD) (second level). [¹²³I] iodobenzamide (IBZM)-SPECT datasets were subjected to an observer-independent regions-of-interest analysis to assess striatal D2R availability. Movement disorder specialists made final clinical diagnoses after a median follow-up time of 12 months. RESULTS: Seventy-eight patients with clinically verified APS (n = 44) or LBD (n = 34) were included in the statistical analysis. The area under the receiver operating characteristic curve for discrimination between APS and LBD was significantly larger for [¹⁸F]FDG-PET (0.94) than for [¹²³I]IBZM-SPECT (0.74; p = 0.0006). Sensitivity/specificity of [¹⁸F]FDG-PET for diagnosing APS was 86%/91%, respectively. Sensitivity/specificity of [¹⁸F]FDG-PET in identifying APS subgroups was 77%/97% for MSA, 74%/95% for PSP, and 75%/92% for CBD. CONCLUSIONS: The diagnostic accuracy of [¹⁸F]FDG-PET for discriminating LBD from APS is considerably higher than for [¹²³I]IBZM-SPECT. [¹⁸F]FDG-PET reliably differentiates APS subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Mosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E. M., Holthoff, V., Kalbe, E., Sorbi, S., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045385 · Cited by 726
Does corticobasal degeneration exist? A clinicopathological re-evaluation
Ling, H., O'Sullivan, S. S., Holton, J. L., Revesz, T., Massey, L. A., Williams, D. R., Paviour, D. C., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq123 · Cited by 394
Neuropathology of variants of progressive supranuclear palsy
Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y., & Josephs, K. A. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833be924 · Cited by 386
Cited by
Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
Morbelli, S., Esposito, G., Arbizu, J., Barthel, H., Boellaard, R., Bohnen, N. I., Brooks, D. J., Darcourt, J., Dickson, J. C., Douglas, D., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04817-8 · Cited by 273
(2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.10.004 · Cited by 253
PET/MR in Dementia and Other Neurodegenerative Diseases
Barthel, H., Schroeter, M. L., Hoffmann, K.-T., & Sabri, O. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.12.003 · Cited by 123
“A concept in this regard relies on additional [(18)F]FDG or MRI as a substitute for the currently often-used dopamine D2/D3 receptor SPECT technique, which is limited regarding a specific differential diagnosis.(15,16) Thus, it was the logical next step to employ combined [(18)F]FDG-PET/MRI for that purpose.”
Metadata
- Authors
- Hellwig, S., Amtage, F., Kreft, A., Buchert, R., Winz, O. H., Vach, W., Spehl, T. S., Rijntjes, M., Hellwig, B., Weiller, C., Winkler, C., Weber, W. A., Tüscher, O., & Meyer, P. T.
- Venue
- Neurology
- Published
- 2012-09-25
- Volume
- 79
- Issue
- 13
- Pages
- 1314-1322
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2088292384
- Cited by
- 174
- References
- 5
- FWCI
- 8.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: [ 18 F]FDG-PET is superior to [ 123 I]IBZM-SPECT for the differential diagnosis of parkinsonism. https://app.cochat.ai/papers/10.1212/wnl.0b013e31826c1b0a
- The paper
- Hellwig, S., Amtage, F., Kreft, A., Buchert, R., Winz, O. H., Vach, W., Spehl, T. S., Rijntjes, M., Hellwig, B., Weiller, C., Winkler, C., Weber, W. A., Tüscher, O., & Meyer, P. T. (2012). [ 18 F]FDG-PET is superior to [ 123 I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. https://doi.org/10.1212/wnl.0b013e31826c1b0a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.